Search
Displaying 21–30 of 662 for “retinitis clinical trial”
-
Clinical Trial to Launch for System Combining Optogenetics and Eyewear
Research NewsThe French biotech GenSight Biologics has received regulatory authorization in the UK to launch the PIONEER Phase 1 \ 2 clinical trial for its GS030 system — a light-sensing gene therapy (optogenetics) coupled with eyewear, which enhances visual stimulation.
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
Research NewsThe 36-participant trial will take place at multiple sites in Australia.
-
First Patient Receives ProQR’s AON Therapy in Clinical Trial for RP Caused by RHO-P23H Mutation
Research NewsThe trial becomes ProQR’s third human study for inherited retinal disease therapies
-
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
Research NewsThe treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
-
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Research NewsMutations in PDE6B are a leading cause of retinitis pigmentosa.
-
First Patient Treated in XLRP Gene Therapy Clinical Trial
Research NewsThe Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
-
Beacon Doses First Patient in its Phase 2/3 VISTA Clinical Trial for XLRP Gene Therapy
Research NewsThe company plans to apply for regulatory approval for the gene therapy with data from VISTA and its earlier clinical trials.
-
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
Research NewsThe company is also launching modifier gene therapy clinical trials for GA and Stargardt disease
-
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
Research NewsThe emerging treatment had shown encouraging results in a Phase ½ clinical trial
.png)
